Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose ‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist RG7697 in people with type 2 diabetes mellitus

ConclusionsDaily doses of RG7697 for 2 weeks were well tolerated by the majority of patients with T2D. Pharmacokinetic data supported once‐daily dosing and pharmacodynamic effect displayed dose‐dependent reductions in fasting and postprandial plasma glucose, without increasing the risk of hypoglycaemia.

Source: Diabetes, Obesity and Metabolism - July 20, 2017 Category: Endocrinology Authors: Christophe Schmitt, Agn ès Portron, Shirin Jadidi, Neena Sarkar, Richard DiMarchi Tags: ORIGINAL ARTICLE Source Type: research